Form 4: Neuronetics Director Receives 30,000 RSU Grant

Director Avinash Amin was granted 30,000 restricted stock units in Neuronetics, Inc. as part of an equity compensation award.

Summary

• Director Avinash Amin acquired 30,000 restricted stock units (RSUs) on May 28, 2026.
• The grant represents a contingent right to receive one share of common stock per RSU.
• Following this transaction, the director's total beneficial ownership of common stock increased to 72,500 shares.
• The award is subject to a one-year vesting period ending May 28, 2027, or upon specific separation or change-in-control events.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard equity grant for a board member.

Risks

• Vesting is contingent upon continuous service, which could be impacted by future board changes or corporate restructuring.

Future Outlook

The RSU award is expected to vest on May 28, 2027, provided the director maintains continuous service with the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the medical device sector to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for publicly traded medical technology companies.
• The one-year vesting schedule is typical for annual director equity awards in the U.S. market.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Vesting of the RSU award on May 28, 2027.

Key Dates

Keywords

Neuronetics, STIM, Form 4, Insider Trading, Equity Compensation, Director Ownership